Iniciar sesión Regístrese gratis

Last updated: 17 February 2022 at 6:15pm EST

Cara Cassino Net Worth




The estimated Net Worth of Cara M Cassino is at least $934 mil dollars as of 25 July 2017. Cara Cassino owns over 8,000 units of ContraFect Corp stock worth over $1,854 and over the last 9 years he sold CFRX stock worth over $0. In addition, he makes $932,262 as Executive Vice President - Research and Development y Chief Medical Officer at ContraFect Corp.

Cara Cassino CFRX stock SEC Form 4 insiders trading

Cara has made over 1 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of CFRX stock worth $9,920 on 25 July 2017.

The largest trade he's ever made was buying 8,000 units of ContraFect Corp stock on 25 July 2017 worth over $9,920. On average, Cara trades about 667 units every 0 days since 2015. As of 25 July 2017 he still owns at least 8,000 units of ContraFect Corp stock.

You can see the complete history of Cara Cassino stock trades at the bottom of the page.





Cara Cassino biography

Dr. Cara M. Cassino M.D. serves as Executive Vice President - Research and Development, Chief Medical Officer of the Company. has served as our Chief Medical Officer since September 2015, also as Executive Vice President of Research and Development since August 2016, and served as a member of the Interim Office of the Chief Executive Officer from March 2017 to June 2017. Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 15 years of experience in pharmaceutical product development with over 20 successful regulatory submissions in the United States and globally. Prior to joining ContraFect, Dr. Cassino served as an independent consultant to various pharmaceutical and biotechnology companies, including Scynexis, from December 2014 to September 2015. Prior to that, she served as Senior Vice President at Forest Laboratories, Inc., a biopharmaceutical company (acquired by Actavis plc, now Allergan plc), where she oversaw Global Clinical Development from 2013 to 2014. While at Forest, she was responsible for pre- and post-marketing clinical activities for a portfolio of 35 compounds, and also clinical due diligence for M&A activity, including the $2.9 billion acquisition of Aptalis Pharma and the $1.1 billion acquisition of Furiex Pharmaceuticals. From 2008 to 2013, Dr. Cassino held a number of senior positions at Pfizer, including Global Medical Team Leader of Pfizer’s antibacterial franchise which included Zyvox (linezolid) and Medicines Development Group VP for Pulmonary Vascular Disease and Rare Diseases. Prior to joining Pfizer, Dr. Cassino also served as Executive Medical Director for the late stage U.S. respiratory franchise at Boehringer-Ingelheim Pharmaceuticals, Inc. and was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at New York University (NYU) School of Medicine for eight years prior to joining industry. Dr. Cassino received her B.A., summa cum laude, in Chemistry and Fine Arts from NYU where she

What is the salary of Cara Cassino?

As the Executive Vice President - Research and Development y Chief Medical Officer of ContraFect Corp, the total compensation of Cara Cassino at ContraFect Corp is $932,262. There are 3 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of $1,875,610.



How old is Cara Cassino?

Cara Cassino is 58, he's been the Executive Vice President - Research and Development y Chief Medical Officer of ContraFect Corp since 2016. There are 10 older and 6 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.

What's Cara Cassino's mailing address?

Cara's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.

Insiders trading at ContraFect Corp

Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz y Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.



What does ContraFect Corp do?

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba



What does ContraFect Corp's logo look like?

ContraFect Corp logo

Complete history of Cara Cassino stock trades at ContraFect Corp

Fecha
#
Empresa
 Persona
Trans.
Transacción
 Acciones Precio por acción Precio total Acciones después de Fuente
25 Jul 2017 CFRX ContraFect Corp Cara M Cassino
Chief Medical Officer
 Comprar 8,000 $1.24 $9,920
25 Jul 2017
8,000 ↗


ContraFect Corp executives and stock owners

ContraFect Corp executives and other stock owners filed with the SEC include: